[Asia Economy Reporter Jang Hyowon] STCube, a bio company developing immuno-oncology drugs, stated on the 27th regarding the sudden stock price drop, “The clinical trials are progressing smoothly without any issues,” and added, “We will respond strongly to malicious rumors related to the company.”
STCube is currently in the final stage of Phase 1 clinical trials for the immune checkpoint inhibitor ‘Nelmastobart (hSTC810).’ The company is conducting procedures to confirm the Dose-Limiting Toxicity (DLT) of the last dosage (15mg/kg) among the six stages of drug administration.
A company representative emphasized, “There are absolutely no factors that could negatively affect the stock price,” and stated, “We will strengthen monitoring to prevent shareholder value from being damaged by baseless malicious rumors and will hold those who violate this accountable through strict legal measures.”
Earlier this month, STCube received an official invitation to the JP Morgan Healthcare Conference and concretized discussions on strategic partnerships such as technology exports with global big pharma companies in the United States. They plan to complete the confirmation of DLT for the last dosage patient by the end of January.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
